RAPP
Rapport Therapeutics, Inc. Common Stock
There isn't enough reported data to score RAPP yet.
RAPP Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Unavailable | |
| Unavailable |
RAPP's profitability is currently weak. There isn't enough data to rate its revenue, cash flow and balance sheet.
RAPP PE Valuation
RAPP has no meaningful PE right now: it lost money over the past year.
RAPP Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong decline | |
| -- | |
| Limited | |
| Low |
Analysts expect RAPP's losses to grow, with revenue declining. However, they disagree widely on these estimates.
RAPP Earnings Per Share
RAPP Quarterly Revenue
RAPP's revenue is growing: $0 last quarter.
| Quarter | Margin | YoY |
|---|---|---|
| Q1 2026 | -121% | N/A |
RAPP Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$41.6M | -$24M |
| Q2 2026 | -$41.5M | -$16.4M |
| Q1 2026 | -$13.1M | +$7.4M |
| Q4 2025 | -$24.9M | -$10.2M |
| Q3 2025 | -$17.6M | -$1M |
| Q1 2025 | -$20.5M | -$1.8M |
| Q4 2024 | -$14.7M | -$2.9M |
| Q3 2024 | -$16.6M | -$11.1M |
RAPP has burned cash in almost every quarter: −$121M over the past year, against −$78M the year before.
RAPP Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.6% | +295K shares |
| 1 year | +26% | +9.8M shares |
RAPP has 48M diluted shares, up 26% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2024 | — |
| Q4 2023 | — |
| Q3 2023 | $4,000 |
| Q2 2023 | — |
| Q1 2023 | — |
RAPP Net Leverage
RAPP's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
RAPP Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 33.9 | Neutral |
| Stochastic | 9.9 | Oversold |
RAPP's weekly RSI is 34 (neutral) and its Stochastic is 10 (oversold).
RAPP PE vs Healthcare Sector
RAPP has no meaningful PE right now: it lost money over the past year.
RAPP Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $28.2 | 8.3% below |
| 20 week MA | $37.5 | 31% below |
| 50 week MA | $34.4 | 25% below |
| 100 week MA | $25.3 | 2.3% above |
RAPP has pulled back, but its long-term trend is still up: it's below its 8-, 20- and 50-week averages, but 2.3% above its 100-week average.
RAPP Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2024 | $20.8 | $19.0 | -8.5% |
| 2025 | $19.0 | $30.2 | +59% |
| 2026 YTD | $30.2 | $25.9 | -14% |
RAPP has finished lower in one of the last two years. It's down 14% so far in 2026.